Can Immunome Inc’s (IMNM) hike of 6.09% in a week be considered a lucky break?

On Friday, Immunome Inc (NASDAQ: IMNM) was 3.42% up from the session before settling in for the closing price of $9.94. A 52-week range for IMNM has been $5.15 – $16.73.

A company in the Healthcare sector has dropped its sales by -38.15% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 57.04%. With a float of $79.33 million, this company’s outstanding shares have now reached $87.01 million.

In an organization with 118 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.0%, operating margin of -1784.14%, and the pretax margin is -1687.08%.

Immunome Inc (IMNM) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 8.87%, while institutional ownership is 85.14%. The most recent insider transaction that took place on Jun 03 ’25, was worth 46,900. In this transaction Director of this company bought 5,000 shares at a rate of $9.38, taking the stock ownership to the 36,415 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Director bought 7,800 for $7.78, making the entire transaction worth $60,684. This insider now owns 31,415 shares in total.

Immunome Inc (IMNM) Latest Financial update

Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.78 earnings per share (EPS) during the time that was less than consensus figure (set at -0.58) by -0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.57 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 57.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.36% during the next five years compared to -38.15% drop over the previous five years of trading.

Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators

You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 71.07.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.09, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.37 in one year’s time.

Technical Analysis of Immunome Inc (IMNM)

Let’s dig in a bit further. During the last 5-days, its volume was 0.69 million. That was inferior than the volume of 1.02 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 36.55%.

During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 78.56%, which indicates a significant increase from 48.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.51 in the past 14 days, which was lower than the 0.56 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $9.65, while its 200-day Moving Average is $9.75. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $10.47. Second resistance stands at $10.65. The third major resistance level sits at $10.93. If the price goes on to break the first support level at $10.01, it is likely to go to the next support level at $9.73. The third support level lies at $9.55 if the price breaches the second support level.

Immunome Inc (NASDAQ: IMNM) Key Stats

There are 87,045K outstanding shares of the company, which has a market capitalization of 894.82 million. As of now, sales total 9,040 K while income totals -292,960 K. Its latest quarter income was 4,020 K while its last quarter net income were -43,400 K.